<DOC>
	<DOCNO>NCT02600988</DOCNO>
	<brief_summary>The purpose study determine whether vitamin D effective prevention graft-versus-host-disease completion allogeneic transplant .</brief_summary>
	<brief_title>Immunomodulatory Effect Vitamin D Allogenic Post-transplant</brief_title>
	<detailed_description>The allogeneic transplant haematopoietic cell treatment option many malignant blood disease . Unfortunately , progression free survival quality life transplant patient limited due development graft-versus-host-disease ( GVHD ) . The development new prophylaxis strategy GVHD base use immunomodulator agent ( allow generation immunotolerance state avoiding use immunosuppression ) essential . The GVHD due cytotoxic effect donor lymphocytes T healthy organ tissue receptor . Calcineurin inhibitor combine methotrexate antibody anti-lymphocytes T use standard prophylaxis . This type antibodies demonstrate efficacy reduce GVHD , increase survival due increase risk relapse serious post-transplant infection . Due interaction VDR ( vitamin D receptor ) present immune system cell , vitamin D able inhibit activation dendritic cell proliferation production cytokine lymphocytes T. Based effect , peri- post- transplant administration vitamin D might decrease risk GVHD allogeneic transplant patient , subsequently decrease immunosuppressant treatment requirement improve prognosis patient .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Age ≥ 18 year The patient accomplish criterion proceed allogeneic transplant The patient legal guardian sign informed consent approve Ethics Committees Clinical Trials Hypercalcemia ≥ 10.5 mg/dl Renal insufficiency creatinine level ≥ 2 x upper limit normal ( 1,1 mg/dl ) Participation others Clinical Trials intervention may affect result study . Patients receive GVHD immunoprophylaxis thymoglobuline GVHD prophylaxis include vitro vivo lymphocytes T depletion ( antilymphocyte T globulin , ALG ) Patients receive transplant haploidentical donor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Graft-Versus-Host-Disease</keyword>
	<keyword>post-allogeneic transplant</keyword>
	<keyword>haematopoietic progenitor</keyword>
</DOC>